Lipid-loading and doxorubicin exposure synergistically enhance cytotoxicity and oxidative stress in hepatoma cells, suggesting implications for obese cancer patients.
Answers are grounded in this paper and cite their sources.
Caution advised for obese cancer patients on doxorubicin; leaves open clinical translation from hepatoma cells.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
AlGhamdi et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: